Soni, Paresh N.

Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)

Bays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 358

Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)

Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 342

Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review

Jacobson, T. A., Glickstein, S. B., Rowe, J. D., & Soni, P. N. (2012) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 263

Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Bhatt, D. L., Steg, P. G., Brinton, E. A., Jacobson, T. A., Miller, M., Tardif, J., Ketchum, S. B., Doyle, R. T., Murphy, S. A., Soni, P. N., et al. (2017) · Clinical Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 183

Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies

Bays, H. E., Ballantyne, C. M., Braeckman, R. A., Stirtan, W. G., & Soni, P. N. (2013) · American Journal of Cardiovascular Drugs

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 141

Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)

Bays, H. E., Braeckman, R. A., Ballantyne, C. M., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2012) · Journal of clinical lipidology

Lipid metabolism and disordersFatty Acid Research and Health

Cited by 94

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study

Brinton, E. A., Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Braeckman, R. A., & Soni, P. N. (2013) · Cardiovascular Diabetology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 70

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies

Ballantyne, C. M., Bays, H. E., Philip, S., Doyle, R. T., Braeckman, R. A., Stirtan, W. G., Soni, P. N., & Juliano, R. A. (2016) · Atherosclerosis

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 52

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies

Ballantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2016) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 47

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Ballantyne, C. M., Braeckman, R. A., Bays, H. E., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2015) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 46